Despite significant advances in its detection, understanding and management, atrial
fibrillation (AF) remains a highly prevalent cardiac arrhythmia with a major impact on …

BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but
anticoagulation is underused in clinical care. The risk of venous thromboembolic disease …

New oral anticoagulants (OACs) that directly inhibit Factor Xa (FXa) or thrombin have been
developed for the long-term prevention of thromboembolic disorders. These novel agents …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Background—The decrease in utility attributed to taking pills for cardiovascular prevention
can have major effects on the cost-effectiveness of interventions but has not been well …

Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Background and Purpose—The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods—A …

Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Aims Atrial fibrillation (AF) patients with contraindications to oral anticoagulation have had
few options for stroke prevention. Recently, a novel oral anticoagulant, apixaban, and …

Vitamin K antagonists have been in wide use for over 70 years. Warfarin, the most
commonly used vitamin K antagonist, has been shown to be highly effective in treating and …